NASDAQ:MESO
Mesoblast Ltd Stock News
$7.35
+0.330 (+4.70%)
At Close: May 17, 2024
Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group
08:03pm, Monday, 08'th Mar 2021
NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today the successful completi
NEW YORK, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Pediatrics (Journal
Why Mesoblast Limited Is Rising Today
01:32pm, Thursday, 11'th Feb 2021
One of its pipeline candidates achieved great results in a late-stage clinical study.
Mesoblast Spikes On Positive Cell Therapy Data in Back Pain Study
05:41am, Thursday, 11'th Feb 2021
Positive results from Mesoblast Limited's (NASDAQ: MESO) chronic back pain treatment trial have boosted investor confidence sending the company's shares higher in the premarket after an announcement
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced results from the Phase 3
Mesoblast Corporate Update
05:35pm, Wednesday, 10'th Feb 2021
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a c
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
01:54pm, Friday, 05'th Feb 2021
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
07:05pm, Thursday, 28'th Jan 2021
NEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its pipeline
Is the Options Market Predicting a Spike in Mesoblast (MESO) Stock?
09:47am, Tuesday, 12'th Jan 2021
Investors need to pay close attention to Mesoblast (MESO) stock based on the movements in the options market lately.
Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference
05:10pm, Monday, 11'th Jan 2021
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that its Chief Executive Offic
Why Mesoblast Stock Skyrocketed Today
04:43pm, Monday, 11'th Jan 2021
The company announced positive results from a clinical trial.
NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced additional results from
Why Mesoblast Stock Plummeted on Friday
04:46pm, Friday, 18'th Dec 2020
Investors are losing confidence because the company disappointed in a late-stage trial for the second time this week.
Mesoblast Webcast – Update on COVID-19 ARDS Trial
10:07pm, Thursday, 17'th Dec 2020
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide an
Mesoblast Update on COVID-19 ARDS Trial
06:32pm, Thursday, 17'th Dec 2020
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with
